Novel rating scales for schizophrenia - Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz)

Schizophrenia Research

Volumn 106, Issue 2-3, 2008, Pages 328-336

  Suzuki, Takefumi ^a,b   Uchida, Hiroyuki ^a,c   Nomura, Kensuke ^a   Takeuchi, Hiroyoshi ^a,d   Nakajima, Shinichiro ^a,d   Tanabe, Akira ^e   Yagi, Gohei ^a,f   Watanabe, Koichiro ^a   Kashima, Haruo ^a  

^a KEIO UNIVERSITY   (Japan)

^b Inokashira Hospital   (Japan)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d Ohizumi Hospital   (Japan)

^e NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^f Suisei Healing Center   (Japan)

Author keywords

FACT Sz; Functioning; Problems; Rating scale; Schizophrenia; TIP Sz

Indexed keywords

ARTICLE; BEHAVIOR DISORDER; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY;

ADULT; AGED; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 56049104897     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.08.013     Document Type: Article

References (47)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. fourth edition (1994), American Psychiatric Association, Washington, D.C.
2. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS) (1983), University of Iowa, Iowa City
3. Andreasen N.C. Scale for the Assessment of Positive Symptoms (SAPS) (1984), University of Iowa, Iowa City
4. Andreasen N.C., Carpenter Jr. W.T., Kane J.M., Lasser R.A., Marder S.R., and Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162 3 (2005) 441-449
5. Bowie C.R., Reichenberg A., Patterson T.L., Heaton R.K., and Harvey P.D. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J. Psychiatry 163 3 (2006) 418-425
6. Brekke J.S., Kohrt B., and Green M.F. Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. Schizophr. Bull. 27 4 (2001) 697-708
7. Buckley P.F., and Stahl S.M. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?. Acta Psychiatr. Scand. 115 2 (2007) 93-100
8. Burlingame G.M., Dunn T.W., Chen S., Lehman A., Axman R., Earnshaw D., and Rees F.M. Selection of outcome assessment instruments for inpatients with severe and persistent mental illness. Psychiatr. Serv. 56 4 (2005) 444-451
9. Burns T., and Patrick D. Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr. Scand. 116 6 (2007) 403-418
10. Collins E.J., Hogan T.P., and Desai H. Measurement of therapeutic response in schizophrenia. A critical survey. Schizophr. Res. 5 3 (1991) 249-253
11. Goldman H.H. Special section on the GAF: editor's introduction. 'do you walk to school, or do you carry your lunch?'. Psychiatr. Serv. 56 4 (2005) 419
12. Green A.I., Canuso C.M., Brenner M.J., and Wojcik J.D. Detection and management of comorbidity in patients with schizophrenia. Psychiatr. Clin. North Am. 26 1 (2003) 115-139
13. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, pp 218-222.
14. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fargas A., Rodríguez M.J., Rele R., Orta J., Kharbeng A., Araya S., Gervin M., Alonso J., Mavreas V., Lavrentzou E., Liontos N., Gregor K., Jones P.B., and SOHO Study Group. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand. Suppl. 416 (2003) 16-23
15. Helldin L., Kane J.M., Karilampi U., Norlander T., and Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr. Res. 93 1-3 (2007) 160-168
16. Hofer A., Kemmler G., Eder U., Edlinger M., Hummer M., and Fleischhacker W.W. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J. Clin. Psychiatry 65 7 (2004) 932-939
17. Honer W.G., Thornton A.E., Sherwood M., MacEwan G.W., Ehmann T.S., Williams R., Kopala L.C., Procyshyn R., and Barr A.M. Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. CNS Drugs 21 9 (2007) 699-714
18. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 2 (1987) 261-276
19. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., and Engel R.R. What does the PANSS mean?. Schizophr. Res. 79 2-3 (2005) 231-238
20. Lindenmayer J.P., Harvey P.D., Khan A., and Kirkpatrick B. Schizophrenia: measurements of psychopathology. Psychiatr. Clin. North Am. 30 3 (2007) 339-363
21. Milev P., Ho B.C., Arndt S., and Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 162 3 (2005) 495-506
22. Morosini P.L., Magliano L., Brambilla L., Ugolini S., and Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 101 4 (2000) 323-329
23. Moos R.H., Nichol A.C., and Moos B.S. Global Assessment of Functioning ratings and the allocation and outcomes of mental health services. Psychiatr. Serv. 53 6 (2002) 730-737
24. Mortimer A.M. Symptom rating scales and outcome in schizophrenia. Br. J. Psychiatry Suppl. 50 (2007) s7-s14
25. Müller M.J., Rossbach W., Dannigkeit P., Müller-Siecheneder F., Szegedi A., and Wetzel H. Evaluation of standardized rater training for the Positive and Negative Syndrome Scale (PANSS). Schizophr. Res. 32 3 (1998) 151-160
26. Naber D., and Vita A. Tools for measuring clinical effectiveness. Eur. Neuropsychopharmacol. 14 Suppl 4 (2004) S435-S444
27. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 10 (1962) 799-812
28. Pedersen G., Hagtvet K.A., and Karterud S. Generalizability studies of the Global Assessment of Functioning-Split version. Compr. Psychiatry 48 1 (2007) 88-94
29. Perlick D.A., Rosenheck R.A., Kaczynski R., Bingham S., and Collins J. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia. Schizophr. Res. 99 1-3 (2008) 192-199
30. Peuskens J. The evolving definition of treatment resistance. J. Clin. Psychiatry 60 Suppl 12 (1999) 4-8
31. Priebe S. Social outcomes in schizophrenia. Br. J. Psychiatr., Suppl. 50 (2007) s15-s20
32. Rabinowitz J., Mehnert A., and Eerdekens M. To what extent do the PANSS and CGI-S overlap?. J. Clin. Psychopharmacol. 26 3 (2006) 303-307
33. Rummel C., Kissling W., and Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst. Rev. 3 (2006) CD005581 Jul 19
34. Santone G., Rucci P., Muratori M.L., Monaci A., Ciarafoni C., and Borsetti G. Attitudes toward medication in inpatients with schizophrenia: a cluster analytic approach. Psychiatry Res. 158 3 (2008) 324-334
35. Santor D.A., Ascher-Svanum H., Lindenmayer J.P., and Obenchain R.L. Item response analysis of the Positive and Negative Syndrome Scale. BMC Psychiatry 7 (2007) 66
36. Suzuki T., Uchida H., Tanaka K.F., Tomita M., Tsunoda K., Nomura K., Takano H., Tanabe A., Watanabe K., Yagi G., and Kashima H. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. Int. Clin. Psychopharmacol. 18 6 (2003) 323-329
37. Suzuki T., Uchida H., Tanaka K.F., Nomura K., Takano H., Tanabe A., Watanabe K., Yagi G., and Kashima H. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int. J. Neuropsychopharmacol. 7 2 (2004) 133-142
38. Suzuki T., Uchida H., Watanabe K., Yagi G., and Kashima H. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28 2 (2004) 361-369
39. Suzuki T., Uchida H., Takeuchi H., Nomura K., Tanabe A., Watanabe K., Yagi G., and Kashima H. Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. Psychopharmacology (Berl) 181 3 (2005) 566-575
40. Suzuki T., Uchida H., Watanabe K., Nomura K., Takeuchi H., Tomita M., Tsunoda K., Nio S., Den R., Manki H., Tanabe A., Yagi G., and Kashima H. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?-a randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology (Berl) 195 2 (2007) 285-295
41. Suzuki T., Uchida H., Watanabe K., Nakajima S., Nomura K., Takeuchi H., Tanabe A., Yagi G., and Kashima H. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum. Psychopharmacol. 23 6 (2008) 455-463
42. Suzuki, T., Uchida, H., Watanabe, K., Kashima, H., in press. Treatment target in schizophrenia. A critical review and a clinical suggestion.
43. Tamblyn R., Abrahamowicz M., Dauphinee D., Wenghofer E., Jacques A., Klass D., Smee S., Blackmore D., Winslade N., Girard N., Du Berger R., Bartman I., Buckeridge D.L., and Hanley J.A. Physician scores on a national clinical skills examination as predictors of complaints to medical regulatory authorities. JAMA 298 9 (2007) 993-1001
44. Tandon R., Devellis R.F., Han J., Li H., Frangou S., Dursun S., Beuzen J.N., Carson W., Corey-Lisle P.K., Falissard B., Jody D.N., Kujawa M.J., L'italien G., Marcus R.N., McQuade R.D., Ray S., Van Peborgh P., and IAQ Validation Study Group. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res. 136 2-3 (2005) 211-221
45. Van Os J., Burns T., Cavallaro R., Leucht S., Peuskens J., Helldin L., Bernardo M., Arango C., Fleischhacker W., Lachaux B., and Kane J.M. Standardized remission criteria in schizophrenia. Acta Psychiatr. Scand. 113 2 (2006) 91-95
46. Von Knorring L., and Lindström E. Principal components and further possibilities with the PANSS. Acta Psychiatr. Scand. Suppl. 388 (1995) 5-10
47. Voruganti L.N., Heslegrave R.J., and Awad A.G. Quality of life measurement during antipsychotic drug therapy of schizophrenia. J. Psychiatry Neurosci. 22 4 (1997) 267-274